A phase II trial evaluated combination treatment with duvelisib, a dual, selective PI3Kδ/γ inhibitor, and docetaxel, a taxane-class of chemotherapeutic drug, in anti-PD-1 refractory recurrent, metastatic HNSCC patients. Here, PDCD1 is linked to head and neck squamous cell carcinoma.